Form 4: Roivant Sciences CFO Executes Net Share Settlement

CFO Richard Pulik disposed of 18,962 common shares to satisfy tax obligations related to RSU vesting.

Summary

• Richard Pulik, CFO of Roivant Sciences Ltd., reported the disposition of 18,962 common shares.
• The transaction occurred on May 20, 2026, at a price of $32.41 per share.
• The disposition was a net settlement to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• Following this transaction, the reporting person maintains beneficial ownership of 278,549 common shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative and related to tax compliance rather than a market-driven divestment.

Positives

• The transaction was a routine administrative action for tax compliance rather than a discretionary sale of stock.

Negatives

• The transaction resulted in a reduction of the CFO's direct equity holdings in the company.

Risks

• None identified; this is a standard regulatory disclosure for tax withholding.

Future Outlook

No forward-looking guidance or strategic outlook provided in this filing.

Industry Context

StockSavvy.ai notes that net settlement transactions are standard practice for corporate executives in the biotechnology sector to manage tax liabilities arising from equity compensation vesting, and they do not typically signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The use of net settlement for RSU tax obligations is consistent with standard executive compensation practices across the pharmaceutical and biotechnology industries.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a routine tax-related settlement.

Key Dates

Keywords

Roivant Sciences, ROIV, Form 4, Insider Trading, CFO, Net Settlement, Tax Withholding